Notably, HSP90 inhibitors can activate NF-κB signaling via fibroblast stimulation through extracellular vesicles (29), while MEK inhibition may reverse tumor cell dedifferentiation and synergize with BET or FAK inhibitors to overcome adaptive resistance (30). This evidence concerns the gene NFKB1 and neoplasm.